| Drug Type Bispecific antibody | 
| Synonyms | 
| Target | 
| Action agonists, inhibitors | 
| Mechanism FZD4 agonists(frizzled class receptor 4 agonists), LRP6 inhibitors(LDL receptor related protein 6 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Glaucoma | Preclinical | Canada  | 14 Jun 2024 | |
| Retinal Diseases | Preclinical | Canada  | 14 Jun 2024 | 






